Baxdrostat geometric mean maximum plasma concentration (Cmax) was 19 ng/mL (%CV: 5.4) and the geometric mean area underneath the time concentration curve from time 0 to infinity (AUC0–inf) was 711 h*ng/mL (%CV: 32) following a single 2 mg dose. Baxdrostat AUC and Cmax increased in a dose‑proportional manner for the 1 and 2 mg doses in patients with hypertension, and steady state was reached by Day 8.
Absorption
Baxdrostat has an absolute bioavailability of 98%. Under fasted conditions, median time to maximum plasma concentration (tmax) was 2.5 hours (min: 1.0 hours, max: 5.0 hours) for the 2 mg dose. Baxdrostat did not show pH- dependent solubility at pharmacologically relevant concentrations.
Effect of Food
No clinically significant differences in baxdrostat pharmacokinetics were observed following administration of a high-fat, high-calorie meal (800 to 1000 calories with approximately 50% of the total caloric content from fat) in healthy subjects.
Distribution
The volume of distribution of baxdrostat at steady state is 205 L. The plasma protein binding of baxdrostat was 74% and the blood to plasma ratio was 0.95 in vitro.
Elimination
The mean effective half-life of baxdrostat was approximately 26 hours (range 23 to 32 hours). The mean total clearance was 2.8 L/h, and the mean renal clearance was 0.46 L/h.
Metabolism
Baxdrostat is primarily metabolized by CYP3A4 to an intermediate ketone metabolite, which is further metabolized by CBR1 (carbonyl reductase 1) to an alcohol metabolite (M2). After a single dose of radiolabeled baxdrostat, the parent compound accounted for 71% of total radioactivity exposure.
Excretion
After administration of a radiolabeled dose of baxdrostat, approximately 69% of the dose was recovered in urine (17% unchanged) and 15% in feces (6% unchanged).
Specific Populations
There were no clinically relevant effects of age (18 to 90 years), sex (37% females), body weight (43 to 224 kg), or race (White, Asian, and Black or African American) on the pharmacokinetics of baxdrostat.
Patients with Renal Impairment
In subjects with moderate or severe renal impairment (eGFR 15 to < 60 mL/min, not on dialysis), Cmax and AUC0–inf of baxdrostat were similar compared to the control group (eGFR ≥ 60 mL/min), with a geometric mean ratio (95% CI) for baxdrostat Cmax of 1.02 (0.82, 1.27) and AUC0–inf of 1.21 (0.81, 1.79). Compared to the control group, subjects with kidney failure treated with intermittent hemodialysis who were administered baxdrostat on a non-dialysis day had a geometric mean ratio (95% CI) for Cmax of 0.88 (0.71, 1.09) and AUC0‑inf of 0.68 (0.46, 0.99) [see Use in Specific Populations (8.6)].
Patients with Hepatic Impairment
In subjects with moderate hepatic impairment (Child-Pugh category B), Cmax and AUC0–inf of baxdrostat were similar to control subjects with normal hepatic function, with a geometric mean ratio (95% CI) for baxdrostat Cmax of 1.13 (0.97, 1.32) and AUC0–inf of 0.95 (0.73, 1.23). Baxdrostat has not been studied in patients with severe hepatic impairment.
Drug Interaction Studies
Clinical Studies
There was no clinically significant difference in baxdrostat exposure based on Cmax (1.30-fold geometric mean increase [95% CI: 1.20, 1.39]) or AUC (1.56-fold geometric mean increase [95% CI: 1.46, 1.66]) when used concomitantly with itraconazole (strong CYP3A and P‑gp inhibitor). There were no differences in the pharmacokinetics of either metformin (MATE1 and MATE2‑K transporter substrate) or the oral contraceptive ethinyl estradiol/levonorgestrel when used concomitantly with baxdrostat.
In Vitro Studies
Cytochrome P450 (CYP450) enzymes: Baxdrostat did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5, and did not induce CYP1A2, CYP2B6, or CYP3A4. Baxdrostat was not a substrate of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A5.
UDP-Glucuronosyltransferase (UGT) enzymes: Baxdrostat did not inhibit UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT2B4, UGT2B7 or UGT2B15.
Transporter systems: Baxdrostat is a P-gp and BCRP substrate, but this is not expected to result in clinically significant drug-drug interactions. Baxdrostat did not inhibit the transporters BCRP, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, or P-gp. Baxdrostat is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.